Type 1 Diabetes Mellitus With Diabetic Nephropathy Clinical Trial
Official title:
Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy
The purpose of the investigators study was to determine the effect of dietary protein restriction on survival and progression to end stage renal disease (ESRD) in diabetic nephropathy.
The study was a prospective, randomized, unmasked, controlled trial carried out at the Steno
Diabetes Center. With concealed randomization the patients were (in blocks of two according
to the level of GFR) assigned to receive either a usual-protein diet or a low-protein diet.
After randomization an iso-caloric low-protein diet of 0.6 g/kg/day was prescribed to
patients in the low-protein diet group. The usual-pro tein diet consisted of the patients'
pre-study diet.
The planned duration of follow-up was four years, scheduled visits every three-months. All
patients gave complete history of medication, underwent examination of weight, urinary
albumin-, sodium- and urea excretion, serum albumin, serum urea, hemoglobin, hemoglobin A1c,
blood pressure, serum total-cholesterol, high-density lipoprotein (HDL) cholesterol.
GFR, serum triglycerides,calcium and phosphorous, anthropometric measurements, nutritional
status and smoking habits were evaluated every six months.
Dietary protein intake was estimated on the basis of three consecutive 24-hour urine samples
completed before each visit, using urinary excretion of urea nitrogen.
GFR was measured by plasma clearance of 51Cr-EDTA over a 4 hour period and standardized for
1.73m2 body surface area using the same surface for each patient during the study.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06072326 -
Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
|
Phase 2 | |
| Completed |
NCT02164279 -
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
|